Philip W. Schiller is an Independent Director at Illumina, Inc. since 2016 and a Trustee at Bowdoin College since 2019. Former positions include Senior Vice President-Worldwide Marketing at Apple, Inc., Director-Product Marketing at FirePower Systems, Inc. from 1993 to 1995, Vice President-Product Marketing at Macromedia, Inc. from 1995 to 1997, Trustee at Boston College from 2010 to 2019, and Manager-Information Technology at Nolan, Norton & Co. BV. Education includes an undergraduate degree from Boston College, conferred in 1982.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Caroline D. Dorsa
Caroline D. Dorsa is the founder of the Institute For Advanced Clinical Trials For Children, founded in 2016, serving as Director Emeritus. Current jobs include Chairman at Biogen, Inc. since 2023, Independent Director at Duke Energy Corp. since 2021, Independent Director at Illumina, Inc. since 2017, Member-Supervisory Board at Biogen GmbH since 2010, and Independent Trustee at Goldman Sachs Credit Income Fund since 2019. Former jobs include Chief Financial Officer, Director & Executive Vice President at PSEG Power LLC from 2014 to 2015; Director at Biogen Idec New Ventures, Inc.; Director at The Newark Museum of Art; Director at Junior Achievement of New Jersey, Inc. from 2009 to 2015; Director at Joule Unlimited Technologies, Inc.; Independent Director at Intellia Therapeutics, Inc. from 2015 to 2023; Chief Financial Officer & Senior Vice President at Gilead Sciences, Inc. from 2007 to 2008; SVP-Global Human, Health, Strategy & Integration at Merck & Co., Inc. from 2008 to 2009; Chief Financial Officer & Executive Vice President at Public Service Electric & Gas Co. from 2010 to 2015; Chief Financial Officer & Executive Vice President at Public Service Enterprise Group, Inc. from 2009 to 2015; Chief Financial Officer at PSEG Energy Holdings LLC; Chief Financial Officer & Senior Vice President at Avaya LLC in 2007; Chief Financial Officer & Executive Vice President at PSEG Services Corp.; Trustee at Goldman Sachs ETF Trust from 2016 to 2021; Trustee at Goldman Sachs MLP Income Opportunities Fund from 2016 to 2021; Independent Trustee at Goldman Sachs MLP & Energy Renaissance Fund from 2016 to 2021; Trustee at Goldman Sachs Private Markets Fund 2018 (B) LLC; Trustee at Goldman Sachs Private Markets Fund 2018 LLC; Independent Trustee at Goldman Sachs Real Estate Diversified Income Fund. Education includes undergraduate degree from Colgate University and MBAistration from Columbia Business School.
Susan E. Siegel
Susan E. Siegel founded Stanford Health Care-Stanford Hospital. Ms. Siegel also currently works at FWH Management Co LLC, as Chairman & Board of Director from 2020, Stanford Medicine, as Co-Chairman from 2017, Illumina, Inc., as Independent Director from 2019, and various other companies. Ms. Siegel also formerly worked at GE Aerospace, as Chief Innovation Officer & CEO-Business Innovations, T.H.E. Engineers, Inc., as Chairman from 2016 to 2020, Affymetrix, Inc., as President & Director from 1998 to 2006, and various other companies. Ms. Siegel received her undergraduate degree from the University of Puerto Rico and graduate degree from Boston University School of Medicine.
Scott Gottlieb
Scott Gottlieb is Independent Chairman at Illumina, Inc. since 2025. Independent Director at Pfizer Inc. since 2019. Director at Wesleyan University, The Mount Sinai Health System, Inc., The Mount Sinai Medical Center, Inc., National Resilience, Inc., National Academy of Medicine (United States), Comanche Biopharma Corp. since 2023, Xaira Therapeutics, Inc. since 2024. Independent Director at Tempus AI, Inc. since 2019, Partner at New Enterprise Associates, Inc. since 2019, Special Partner at NEA Management Co. LLC since 2019, and Independent Director at UnitedHealth Group, Inc. since 2025. Formerly Independent Director at CombiMatrix Corp. from 2009 to 2016, Managing Director at T.R. Winston & Co. LLC from 2013 to 2017, Independent Member of the Board of Directors at Bravo Health, Inc. from 2009 to 2011, Member of the Board of Directors at MedAvante, Inc. from 2007 to 2017, Independent Member of the Board of Directors at Molecular Insight Pharmaceuticals, Inc. from 2007 to 2010, Director at Aseko, Inc. and Targeted Medical Pharma, Inc., Director at EMI Holding, Inc. in 2015, Independent Member of the Board of Directors at American Pathology Partners, Inc. from 2012 to 2017, Member of the Board of Directors at Gradalis, Inc. from 2015 to 2017, Director at Tolero Pharmaceuticals, Inc. from 2015 to 2016, Independent Member of the Board of Directors at Daiichi Sankyo, Inc. from 2015 to 2017, Member of the Board of Directors at Aptiv Solutions, Inc. from 2012 to 2014, Analyst at Alex. Brown & Sons, Inc. from 1994 to 1995, Senior Adviser to the Administrator at Centers for Medicare & Medicaid Services (US), Deputy Commissioner-Medical & Scientific Affairs at US Food & Drug Administration from 2005 to 2007, and Commissioner at US Food & Drug Administration from 2017 to 2019. Education includes undergraduate degree from Wesleyan University and doctorate from Icahn School of Medicine at Mount Sinai.
Scott B. Ullem
Mr. Scott B. Ullem is an Independent Director at Illumina, Inc., a Chief Financial Officer at Edwards Lifesciences Foundation and a Chief Financial Officer & Vice President at Edwards Lifesciences Corp. He is on the Board of Directors at Illumina, Inc. and Egnite, Inc. Mr. Ullem was previously employed as a Chief Financial Officer & Vice President by CAS Medical Systems, Inc., an Independent Director by Berry Global Group, Inc., a Chief Financial Officer & Vice President by Bemis Co., Inc., a Managing Director by Banc of America Securities LLC, a Managing Director by Bank of America Corp., and a MD-Investment Banking Services Group by Goldman Sachs & Co. LLC. He also served on the board at Berry Global, Inc. and The Aspen Institute, Inc. He received his undergraduate degree from DePauw University and an MBA from Harvard Business School.
Jacob Thaysen
Jacob Thaysen is the founder of Cantion A. Dr. Thaysen is currently Chairman at Analytical Life Science & Diagnostics Association, Director, Chief Executive & Commercial Officer at Illumina, Inc. since 2023, Director at Lasergen, Inc., and Member of the American Cancer Society's CEOs Against Cancer. Formerly, Dr. Thaysen was Director at Gen9, Inc., SVP & President-Life Sciences & Applied Markets at Agilent Technologies, Inc. from 2018 to 2023, Vice President-Research & Development at Cytologix Corp., and Vice President-System Development, R&D at Dako Denmark ApS from 2012 to 2013. Education includes graduate and doctorate degrees from the Technical University of Denmark, conferred in 1998 and 2001 respectively.
Anna S. Richo
Anna S. Richo is currently an Independent Director at Exelon Corp. since 2023, an Independent Director at Illumina, Inc. since 2024, and holds director positions at Twin Cities Diversity in Practice, Children's Health Care, and Cargill Foundation. Also serves as a Trustee at DePaul University. Former roles include Vice Chairman at California Manufacturers & Technology Association from 2000 to 2003, Director at Cytyc Corp. from 1998 to 2003, Independent Director at Adamas Pharmaceuticals LLC from 2020 to 2021, Vice President at Baxter Healthcare Corp. in 1996, Attorney at The NutraSweet Co., Chief Compliance Officer & SVP at Amgen Ventures LLC, Associate at Peterson & Ross, Chief Compliance Officer & Senior Vice President at Amgen, Inc. from 2008 to 2012, Executive Vice President & General Counsel at UCB SA from 2012 to 2019, and Chief Compliance Officer, SVP & General Counsel at Cargill, Inc. from 2019 to 2024. Education includes undergraduate studies at Cornell University and graduate studies at DePaul University College of Law.
David P. King
Mr. David P. King is an Independent Non-Executive Director at Smith & Nephew plc, an Operating Partner at Healthquest Capital Management Co LLC, an Executive Chairman at ScribeAmerica, Inc., a Non-Executive Chairman at Privia Health Group, Inc., a Managing Member at Kingman LLC and a Chairman & Chief Executive Officer at Fortis Life Sciences LLC. He is on the Board of Directors at Illumina, Inc., Smith & Nephew plc, BioAgilytix Labs, LLC, Novant Health, Inc., binx health, inc., Emily Krzyzewski Family Life Center, Inc., Binx Health Ltd., Personalized Medicine Coalition, Seattle Science Foundation, Durham Academy, Inc. and Program for Appropriate Technology in Health. Mr. King was previously employed as a Non-Executive Chairman by ZimVie, Inc., an Executive Chairman by The Health Channel, Inc., an Operating Partner by PPC Investment Partners LP, a Trustee by Elon University, an Independent Director by Cardinal Health, Inc., a Chairman by American Clinical Laboratory Association, a President by US Pathology Labs, Inc., a Chairman by Laboratory Corporation of America Holdings, a Partner by Hogan & Hartson LLP, and a Chairman by PATH, Inc. He also served on the board at VaxCare Corp. and CancerGuide Diagnostics, Inc. He received his undergraduate degree from Princeton University and a graduate degree from The University of Pennsylvania Law School.
提供，免责声明：天汇财经、Factset及其他信息供应商努力确保所提供信息的准确性和可靠性，但对于其正确性或可靠性则不予担保，且对于因不正确或疏漏所造成的任何损失或损坏概不负责(无论是有关民事过失、合同或其他方面)。